Imeroprubart Biosimilar Monoclonal Antibody (FcRn) for Research

Cat No.: GMP-Bios-INN-1231

Anti-FCGRT/FcRn therapeutic antibody (Pre-made Imeroprubart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Imeroprubart (development codes IMVT-1402/HL161ANS) is a monoclonal antibody targeting FcRn (neonatal Fc receptor, FCGRT). It is developed by Immunovant for autoimmune disorders. Further development details are under investigation.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1231-1mg 1mg 3090
GMP-Bios-INN-1231-10mg 10mg
GMP-Bios-INN-1231-100mg 100mg
GMP-Bios-INN-1231-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Imeroprubart biosimilar, Whole mAb, Anti-FCGRT/FcRn Antibody: Anti-FcRn/FCGRT/IgG receptor FcRn large subunit p51/IgG Fc fragment receptor transporter alpha chain therapeutic antibody
INN Name Imeroprubart
Target FCGRT/FcRn
Format Whole mAb
Derivation Human
Species Reactivity Human
CH1+2+3 Isotype G1
VD LC Lambda
Highest_Clin_Trial (Jan '20) TBC
Est. Status Active
100% SI Structure None
99% SI Structure None
95-98% SI Structure None
Year Proposed 2024
Year Recommended na
Companies TBC
Conditions Approved TBC
Conditions Active TBC
Conditions Discontinued TBC
Production na
Development Tech TBC